These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
220 related items for PubMed ID: 15384958
21. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D. Diabetes Care; 2006 Jun; 29(6):1220-6. PubMed ID: 16731999 [Abstract] [Full Text] [Related]
24. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. Koren MJ, Hunninghake DB, ALLIANCE Investigators. J Am Coll Cardiol; 2004 Nov 02; 44(9):1772-9. PubMed ID: 15519006 [Abstract] [Full Text] [Related]
25. [How can primary prevention of coronary heart disease be improved in general practice?]. Wicklmayr M, Rett K, Standl E. Med Klin (Munich); 1994 Apr 15; 89(4):184-6, 229. PubMed ID: 8015531 [Abstract] [Full Text] [Related]
27. Dyslipidemia in type 2 diabetes. Krauss RM, Siri PW. Med Clin North Am; 2004 Jul 15; 88(4):897-909, x. PubMed ID: 15308384 [Abstract] [Full Text] [Related]
31. Frequency of statin use in type 2 diabetics having macrovascular disease- at a Tertiary Care Hospital of Karachi. Basit A, Hydrie MZ, Hakeem R, Ahmedani MY, Masood Q. J Ayub Med Coll Abbottabad; 2004 Jul 15; 16(4):60-4. PubMed ID: 15762067 [Abstract] [Full Text] [Related]
32. Inadequate treatment of dyslipidemia in people with type 2 diabetes: quality assessment of diabetes care in a Danish County. Kolding Kristensen J, Lauritzen T. Scand J Prim Health Care; 2006 Sep 15; 24(3):181-5. PubMed ID: 16923628 [Abstract] [Full Text] [Related]
36. Levels of dyslipidaemia and improvement in its management in England: results from the Health Survey for England 2003. Primatesta P, Poulter NR. Clin Endocrinol (Oxf); 2006 Mar 15; 64(3):292-8. PubMed ID: 16487439 [Abstract] [Full Text] [Related]
38. Gender disparities in lipid-lowering therapy among veterans with diabetes. Vimalananda VG, Miller DR, Palnati M, Christiansen CL, Fincke BG. Womens Health Issues; 2011 Mar 15; 21(4 Suppl):S176-81. PubMed ID: 21724138 [Abstract] [Full Text] [Related]
39. Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS). Zhao SP, Lu ZL, Du BM, Chen Z, Wu YF, Yu XH, Zhao YC, Liu L, Ye HJ, Wu ZH, China Coronary Secondary Prevention Study (CCSPS). J Cardiovasc Pharmacol; 2007 Feb 15; 49(2):81-4. PubMed ID: 17312447 [Abstract] [Full Text] [Related]
40. General practitioners' tacit and stated policies in the prescription of lipid lowering agents. Evans JS, Harries C, Dennis I, Dean J. Br J Gen Pract; 1995 Jan 15; 45(390):15-8. PubMed ID: 7779468 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]